*
Corresponding authors
a
Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
E-mail:
kr21f@nih.gov
b
University of New England, College of Osteopathic Medicine, Biddeford, ME, USA
c
Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA
d
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA
e
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland, USA